Why Invest?

• Electromed addresses the significantly underpenetrated and growing bronchiectasis market, and is the only publicly-traded "pure play" on this theme.
• An aging population and increasing patient and physician awareness of the benefits of High Frequency Chest Wall Oscillation ("HFCWO") therapy continue to drive industry growth.
• SmartVest®, Electromed's innovative HFCWO device, leads the way in features designed to improve patient comfort and compliance with prescribed treatment schedules.
• Electromed provides unparalleled patient care and reimbursement support.
• Electromed's differentiated direct-to-patient distribution model drives high gross margins, positive operating cash flow and profitability.
• Proven and focused management team driven to serve the patient, physician and payer, while creating value for shareholders.
• Strong organic growth track record and compelling growth strategy.